Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Corcept Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 98.3%. For fiscal 2025 it was 98.3%, against 98.4% the year before. The highest annual figure on record is 98.7% in fiscal 2022.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.3% | −0.1 |
| FY2024 | Dec 31, 2024 | 98.4% | −0.3 |
| FY2023 | Dec 31, 2023 | 98.7% | −0.0 |
| FY2022 | Dec 31, 2022 | 98.7% | +0.1 |
| FY2021 | Dec 31, 2021 | 98.6% | +0.1 |
| FY2020 | Dec 31, 2020 | 98.4% | +0.2 |
| FY2019 | Dec 31, 2019 | 98.2% | +0.3 |
| FY2018 | Dec 31, 2018 | 97.9% | +0.2 |
| FY2017 | Dec 31, 2017 | 97.8% | +0.3 |
| FY2016 | Dec 31, 2016 | 97.5% | +0.2 |
| FY2015 | Dec 31, 2015 | 97.3% | +0.6 |
| FY2014 | Dec 31, 2014 | 96.7% | −1.9 |
| FY2013 | Dec 31, 2013 | 98.6% | +1.4 |
| FY2012 | Dec 31, 2012 | 97.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 98.4% | +0.2 |
| Q1 FY2026 | Mar 31, 2026 | 98.3% | −0.2 |
| Q4 FY2025 | Dec 31, 2025 | 98.7% | +0.4 |
| Q3 FY2025 | Sep 30, 2025 | 97.8% | −0.6 |
| Q2 FY2025 | Jun 30, 2025 | 98.2% | −0.2 |
| Q1 FY2025 | Mar 31, 2025 | 98.5% | +0.2 |
| Q4 FY2024 | Dec 31, 2024 | 98.4% | −0.2 |
| Q3 FY2024 | Sep 30, 2024 | 98.4% | −0.2 |
| Q2 FY2024 | Jun 30, 2024 | 98.5% | −0.2 |
| Q1 FY2024 | Mar 31, 2024 | 98.3% | −0.4 |
| Q4 FY2023 | Dec 31, 2023 | 98.6% | +0.0 |
| Q3 FY2023 | Sep 30, 2023 | 98.7% | −0.0 |
| Q2 FY2023 | Jun 30, 2023 | 98.7% | −0.1 |
| Q1 FY2023 | Mar 31, 2023 | 98.7% | +0.0 |
| Q4 FY2022 | Dec 31, 2022 | 98.6% | −0.1 |
| Q3 FY2022 | Sep 30, 2022 | 98.7% | +0.0 |
| Q2 FY2022 | Jun 30, 2022 | 98.7% | +0.2 |
| Q1 FY2022 | Mar 31, 2022 | 98.7% | +0.3 |
| Q4 FY2021 | Dec 31, 2021 | 98.6% | +0.1 |
| Q3 FY2021 | Sep 30, 2021 | 98.7% | +0.1 |
| Q2 FY2021 | Jun 30, 2021 | 98.5% | −0.1 |
| Q1 FY2021 | Mar 31, 2021 | 98.4% | +0.4 |
| Q4 FY2020 | Dec 31, 2020 | 98.5% | +0.2 |
| Q3 FY2020 | Sep 30, 2020 | 98.6% | +0.4 |
| Q2 FY2020 | Jun 30, 2020 | 98.6% | +0.5 |
| Q1 FY2020 | Mar 31, 2020 | 98.0% | −0.1 |
| Q4 FY2019 | Dec 31, 2019 | 98.4% | +0.7 |
| Q3 FY2019 | Sep 30, 2019 | 98.2% | +0.2 |
| Q2 FY2019 | Jun 30, 2019 | 98.1% | −0.1 |
| Q1 FY2019 | Mar 31, 2019 | 98.1% | +0.1 |
| Q4 FY2018 | Dec 31, 2018 | 97.6% | −0.2 |
| Q3 FY2018 | Sep 30, 2018 | 98.0% | +0.3 |
| Q2 FY2018 | Jun 30, 2018 | 98.1% | +0.3 |
| Q1 FY2018 | Mar 31, 2018 | 98.0% | +0.3 |
| Q4 FY2017 | Dec 31, 2017 | 97.8% | +0.2 |
| Q3 FY2017 | Sep 30, 2017 | 97.7% | +0.8 |
| Q2 FY2017 | Jun 30, 2017 | 97.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 97.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 97.6% | – |
| Q3 FY2016 | Sep 30, 2016 | 96.9% | – |
See a number that looks wrong?